Glioma

REVIEW
Year
: 2022  |  Volume : 5  |  Issue : 3  |  Page : 90--98

Progress on TTFields combined with other therapies for glioblastoma treatment: A narrative review


Yong Cao, Haibin Wu, Bin Tang, Meihua Li, Yilv Wan, Jian Duan, Jiang Xu 
 Department of Neurosurgery, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, China

Correspondence Address:
Prof. Jian Duan
Department of Neurosurgery, The First Affiliated Hospital of Nanchang University, 17 Yong Wai Zheng Street, Nanchang, Jiangxi Province
China
Dr. Jiang Xu
Department of Neurosurgery, The First Affiliated Hospital of Nanchang University, 17 Yong Wai Zheng Street, Nanchang, Jiangxi Province
China

Glioma is the most common primary malignant tumor in the skull, and the current treatment remains a combination of surgery, radiotherapy (RT), and chemotherapy. Radiation therapy plays an important role in the treatment of glioma, and currently, surgical resection under molecular pathology guidance plus postoperative radiation therapy and chemotherapy is the standard treatment protocol for primary glioma, but its widespread use is limited by its radiotoxicity. Meanwhile, with the increasing development of new technologies in the medical field of tumor treatment electric fields, there has been some improvement in the treatment and prognosis of glioma. TTFields are a noninvasive anti-cancer modality consisting of low-intensity (1–3 V/cm), medium-frequency (100–300 kHz), alternating current electric fields delivered through an array of skin sensors to provide optimal coverage of the tumor site. TTFields target cancer cells through multiple mechanisms of action, including inhibition of proliferation, migration, and invasion, disruption of DNA repair and angiogenesis, antitumor effects, induction of apoptosis, and immunogenic cell death. TTFields alone have good efficacy against tumors, and with the gradual development of technologies such as immune and targeted therapies, TTFields are now more frequently studied in combination with chemotherapy, RT, immunotherapy, and immunotherapy. At present, the treatment methods of glioma include surgery, chemotherapy, RT, immunotherapy and targeted therapy. This article will summarize the research progress of TTFields combined with other therapies to provide a reference for the treatment of glioblastoma.


How to cite this article:
Cao Y, Wu H, Tang B, Li M, Wan Y, Duan J, Xu J. Progress on TTFields combined with other therapies for glioblastoma treatment: A narrative review.Glioma 2022;5:90-98


How to cite this URL:
Cao Y, Wu H, Tang B, Li M, Wan Y, Duan J, Xu J. Progress on TTFields combined with other therapies for glioblastoma treatment: A narrative review. Glioma [serial online] 2022 [cited 2022 Dec 1 ];5:90-98
Available from: http://www.jglioma.com/article.asp?issn=2589-6113;year=2022;volume=5;issue=3;spage=90;epage=98;aulast=Cao;type=0